Of 10 guidance figures from Amgen's earnings releases that Stock Atlas has scored against the reported result, 1 came in above the guide, 5 in range and 4 below. It met or beat its own guidance 60% of the time.
| Period | Measure | Guided | Reported | Result |
|---|---|---|---|---|
| FY2025 | Capital Expenditures | $2.20B to $2.30B | $1.86B | below |
| FY2025 | Revenue | $35.80B to $36.60B | $36.75B | above |
| FY2024 | Capital Expenditures | $1.30B | $1.10B | below |
| FY2024 | Revenue | $33.00B to $33.80B | $33.42B | in range |
| FY2023 | Total revenues | $28.00B to $28.40B | $28.19B | in range |
| FY2022 | Total revenues | $26.00B to $26.30B | $26.32B | in range |
| FY2021 | Total revenues | $25.80B to $26.20B | $25.98B | in range |
| FY2021 | Capital Expenditures | $900.00M | $880.00M | below |
Above means the reported figure beat the top of the range, in range that it landed inside it or on a point guide, below that it missed. Every guide and revision, and screens across companies, are in the research platform.
Do companies beat their own guidance? The study · Back to Amgen financials
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Amgen (AMGN) guidance record”, stockatlas.com/companies/AMGN/guidance/, data as of 3 November 2026. Links to this page are welcome.
